JPRN-UMIN000000906已完成未知
Rituximab treatment of cyclophosphamide-resistant patients with ANCA-associated vasculitis - RiCRAV
Research Comittee of Intractable Vasculitis Syndrome of the Ministry of Health, Labor and Welfare of Japan0 个研究点目标入组 15 人开始时间: 2007年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. severe infection (including tuberculosis, HCV, HBV and HIV). 2. history of hypersensitivity to mouse-derived protein 3. congestive heart failure with NYHA III or IV
研究者
相似试验
进行中（未招募）
不适用
First line treatment with Rituximab asociated to CVP plus Interferon in Follicular Lymphoma. Phase II study.Asociación de Rituximab al esquema CVP + Interferón en el tratamiento de primera línea del linfoma folicular - R-CVP-IFEUCTR2005-004761-42-ESFundacion Leucemia y Linfoma
进行中（未招募）
不适用
Rituximab treatment in patients with tjyroid associated that do not respond to intravenous steroids or relapse after intravenous steroid treatmentThyroid associated opthalmopathyEUCTR2011-000899-33-SEDepartment of Endocrinology, Sahlgrenska University Hospital50
尚未招募
不适用
The Effect of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) on Overall Survival of Patients with Relapsed Diffuse Large B-Cell Lymphoma Post-Autologous Stem Cell Transplantdiffuse large B-cell lymphomaACTRN12610000803099Haematology and Oncology Clinics (HOCA) Research Centre150
尚未招募
不适用
Rituximab administration for chronic antibody-mediated rejection after kidney transplantatioAntibody-mediated rejection after kidney transplantationJPRN-UMIN000018567Department of Nephrology and Hypertension, Saitama Medical Center, Saitama Medical University1
已完成
3 期
Clinical study of Rituximab for inhibition of antibody mediated rejection in ABO-incompatible kidney transplantatioChronic kidney disease patient to whom ABO incompatibility kidney transplantation is planned.JPRN-UMIN000006635Zenyaku Kogyo Co., Ltd.23